Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Prime Medicine (PRME) Equity Average (2021 - 2025)

Prime Medicine (PRME) has disclosed Equity Average for 5 consecutive years, with $141.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Average fell 17.5% year-over-year to $141.3 million, compared with a TTM value of $141.3 million through Dec 2025, down 17.5%, and an annual FY2025 reading of $137.0 million, down 4.26% over the prior year.
  • Equity Average was $141.3 million for Q4 2025 at Prime Medicine, up from $111.3 million in the prior quarter.
  • Across five years, Equity Average topped out at $297.5 million in Q1 2023 and bottomed at -$209.1 million in Q3 2022.
  • Average Equity Average over 5 years is $91.0 million, with a median of $141.3 million recorded in 2025.
  • The sharpest move saw Equity Average skyrocketed 284.13% in 2023, then plummeted 61.9% in 2025.
  • Year by year, Equity Average stood at -$125.3 million in 2021, then soared by 137.17% to $46.6 million in 2022, then surged by 250.99% to $163.5 million in 2023, then grew by 4.78% to $171.3 million in 2024, then decreased by 17.5% to $141.3 million in 2025.
  • Business Quant data shows Equity Average for PRME at $141.3 million in Q4 2025, $111.3 million in Q3 2025, and $83.9 million in Q2 2025.